COMMUNICATION
Viral Ski Inhibits Retinoblastoma Protein (Rb)-mediated Transcriptional Repression in a Dominant Negative Fashion*

Fumino TokitouDagger §, Teruaki NomuraDagger , Md Matiullah KhanDagger parallel , Sunil C. Kaul**, Renu WadhwaDagger Dagger , Takashi YasukawaDagger , Isao Kohno§§, and Shunsuke IshiiDagger §¶¶

From the Dagger  Laboratory of Molecular Genetics, Tsukuba Life Science Center, RIKEN, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan, the § Institute of Medical Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-0006, Japan, the ** National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, 1-1 Higashi, Tsukuba, Ibaraki 305-0046, Japan, the Dagger Dagger  Chugai Research Institute for Molecular Medicine, 153-2 Nagai, Niihari, Ibaraki 300-4101, Japan, the §§ Iatron Laboratories Inc., 1460-6 Mitodai, Tako, Katori, Chiba 289-2247, Japan, and the  CREST (Core Research for Evolutional Science and Technology), JST

    ABSTRACT
Top
Abstract
Introduction
References

The mechanism by which the viral oncogene ski (v-ski) transforms chicken embryo fibroblasts is currently unknown. Recently, the c-ski gene product (c-Ski) was found to bind to N-CoR (nuclear hormone receptor co-repressor), an element implicated in transcriptional repression mediated by multiple transcriptional repressors including the nuclear hormone receptors and Mad. c-Ski is required for transcriptional repression mediated by Mad involved in negative regulation of cellular proliferation. v-Ski abrogates Mad-induced transcriptional repression in a dominant negative fashion. Here we report that v-Ski also inhibits transcriptional repression mediated by Rb, another tumor suppressor gene product. Rb forms a complex with c-Ski, Sin3A, and histone deacetylase (HDAC) via direct binding to c-Ski and HDAC. c-Ski is required for the transcriptional repression mediated by Rb. These results suggest that inhibition of Rb activity contributes, at least partly, to transformation by v-Ski.

    INTRODUCTION
Top
Abstract
Introduction
References

The oncogene v-ski was originally identified in avian Sloan-Kettering viruses and found to transform chicken embryo fibroblasts (1). The human c-ski1 proto-oncogene product (c-Ski) is a 728-amino acid nuclear protein, and the N- and C-terminal regions of c-Ski possess a cysteine-rich and a coiled-coil region, respectively (2, 3). The v-Ski protein lacks a 292-amino acid region from the C terminus of c-Ski, but still contains the N-proximal cysteine-rich region (4). This N-proximal region is responsible for the cellular transformation capacity of ski (5). The ski gene family comprises two members, ski and sno (ski-related novel gene) (2), and both have been shown to share clear homology in their N- and C-terminal regions (2, 6). Recently we found that c-Ski directly binds to N-CoR (nuclear hormone receptor co-repressor) (28). N-CoR was originally identified as a co-repressor that binds to and mediates transcriptional repression by nuclear hormone receptors (8). Another co-repressor, SMRT, shows striking homology to N-CoR (9). N-CoR also forms a complex with mammalian Sin3 orthologues (mSin3A and mSin3B). The binding of mSins to histone deacetylase (HDAC) suggested that transcriptional repression through N-CoR involves deacetylation of nucleosomal histones (10-14). The basic helix-loop-helix proteins of the Mad family act as transcriptional repressors after heterodimerization with Max (15). Mad interacts with the HDAC complex through direct binding to mSin3, and N-CoR is required for Mad-induced transcriptional repression (10-14). We demonstrated that N-CoR binds to the N-terminal region of c-Ski and that this interaction is also required for transcriptional repression mediated by Mad and the thyroid hormone receptor beta  (28). The same target sequence of Mad/Max, the so-called E-box, is also recognized by a heterodimer of Myc/Max that activates transcription. It is believed that Myc/Max enhances cellular proliferation or transformation, whereas Mad/Max leads to suppression of proliferation or induction of terminal differentiation in a wide range of cell types (16, 17). Our data indicated that v-Ski blocks Mad-induced transcriptional repression in a dominant negative fashion (28), suggesting that inhibition of Mad function contributes to transformation by v-Ski.

In addition to Mad, the retinoblastoma protein (Rb) encoded by another tumor suppressor gene also binds to HDAC (18-20). Rb regulates the G1/S transition in the cell cycle by silencing a group of target genes regulated by E2F transcription factors (21, 22). Rb binds to the activation domain of E2F and then actively represses the promoter by recruiting HDAC. The pocket region of Rb, which contains two subdomains, termed A and B, are responsible for interaction with HDAC (18-20). Although HDAC forms a complex with mSin3, N-CoR, and Ski, it remains unknown whether Rb can form a complex with any of these components of the N-CoR complex. To understand the molecular mechanism of transformation by v-Ski, we examined whether c-Ski forms a complex with Rb and whether v-Ski abrogates Rb-induced transcriptional activation as in the case of Mad. Our results indicate that c-Ski is needed for the transcriptional repression mediated by Rb and that v-Ski abrogates Rb-induced transcriptional repression.

    MATERIALS AND METHODS

Co-immunoprecipitation-- HeLa cells were lysed in lysis buffer consisting of PBS, 0.1% Nonidet P-40, 10% glycerol, and protease inhibitor mixture (Boehringer Mannheim). CV-1 cells were lysed in lysis buffer consisting of PBS, 1 mM NaF, 1 mM Na3VO4, 0.1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 10% glycerol, and protease inhibitor mixture (Boehringer Mannheim). Lysates were immunoprecipitated using anti-c-Ski monoclonal antibodies (28), anti-Sno monoclonal antibodies, anti-Rb antibody G3-245 or XZ91 (Pharmingen), anti-Gal4 antibody (Santa Cruz Biotechnology Inc.), or control IgG, and the immune complex was analyzed by Western blotting using the anti-Rb, anti-N-CoR (28), anti-c-Ski, anti-mSin3A (Santa Cruz Biotechnology Inc.), or anti-HDAC1 (Santa Cruz Biotechnology Inc.) antibodies and ECL detection reagents (Amersham Pharmacia Biotech). Anti-c-Ski and anti-Sno monoclonal antibodies were prepared using bacterially expressed full-length c-Ski and Sno proteins, respectively.

To examine the effect of v-Ski on complex formation among Rb, HDAC1, and Ski, CV-1 cells were transfected with a mixture of 1 µg of the c-Ski or v-Ski expression plasmid, 3 µg of the Gal4-Rb expression plasmid, and 1 µg of the HDAC1 expression plasmid using LipofectAMINETM (Life Technologies Inc.). The plasmid to express Gal4-Rb containing the DNA-binding domain of Gal4 (amino acids 1-174) and the repressor domain of Rb (amino acids 379-792) was constructed using the cytomegalovirus promoter-containing vector pcDNA3 (Invitrogen). The HDAC1 expression plasmid was constructed using pcDNA3, and the c-Ski and v-Ski expression plasmids were described (28). Lysates were prepared and immunoprecipitated using anti-Gal4 antibody (UBI) or control IgG as described above, and the immune complex was analyzed by Western blotting using the anti-HDAC1 antibody (Santa Cruz Biotechnology Inc.).

In Vitro Binding Assay-- To express the GST-Rb fusion protein containing the pocket region of human Rb (amino acids 372-787) in Escherichia coli, a plasmid was constructed by the polymerase chain reaction-based method using the pGEX-2T vector (Amersham Pharmacia Biotech). The modified pSP65 vector pSPUTK (Stratagene) was used for in vitro transcription/translation of the various forms of Rb and c-Ski. The various deletion mutants of c-Ski have been described previously (28), and the Rb deletion mutants were constructed using appropriate enzyme sites. The Rb mutants contained deletions of one of the following regions; Delta B (amino acids 600-928), Delta A (amino acids 302-600), Delta A + B (amino acids 414-928), or A + B (amino acids 1-371 and amino acids 789-928). The preparation of GST fusion proteins, the in vitro translation of various forms of Rb and c-Ski, and the binding assays were done essentially as described (28) except for the use of a binding buffer consisting of 10 mM Hepes (pH 7.6), 0.1 M KCl, 2.5 mM MgCl2, 0.5 mM dithiothreitol, 0.05% Nonidet P-40, and 0.1 mg/ml bovine serum albumin and the use of PBS for washing.

Single-cell Microinjection Assay-- The antibody injection experiments using the Gal4-Rb expression plasmid and the anti-c-Ski and anti-Sno polyclonal antibodies were performed as described (28).

Effect of Ski on Rb-induced Transcriptional Repression-- To investigate the effect of v-Ski on Gal4-Rb-mediated transcriptional repression, a mixture of 3 µg of the Gal site-containing luciferase reporter, 0.02 µg of Gal4-Rb or the Gal4 expression plasmid, and 1, 2, or 3 µg of the plasmid to express c-Ski or v-Ski and 0.5 µg of internal control plasmid pRL-TK was transfected into CV-1 cells using the CaPO4 method, and luciferase assays were performed. The total amount of plasmid DNA was adjusted to 15 µg by addition of the control plasmid DNA lacking the cDNA. To examine the effect of Ski on E2F-dependent transcriptional activation, a mixture of 0.1 µg of the E2F1 site-containing luciferase reporter, 0.05 µg of the E2F1 expression plasmid or the control DNA, and 1.5, 2, or 2.5 µg of the v-Ski expression plasmid and 0.1 µg of the internal control plasmid pRL-TK was transfected into CV-1 cells using LipofectAMINETM (Life Technologies, Inc.), and luciferase assays were performed. The total amount of plasmid DNA was adjusted to 3 µg by addition of the control plasmid DNA lacking the cDNA. The E2F site-containing reporter was described previously (23). The pcDNA1 vector (Invitrogen) containing the cytomegalovirus promoter was used to express E2F1.

    RESULTS

To investigate whether Rb forms a complex with c-Ski in vivo, co-immunoprecipitation assays were performed (Fig. 1A). The cell lysates were prepared from HeLa cells and immunoprecipitated with anti-c-Ski, anti-Sno, or control anti-Gal4 antibody. Rb was co-precipitated with anti-c-Ski or anti-Sno antibodies but not with the control anti-Gal4 antibody. To examine complex formation between the endogenous Rb protein and mSin3A, co-immunoprecipitation was performed using CV-1 cells. The anti-Rb antibody XZ91 co-immunoprecipitated mSin3A, whereas the anti-Rb antibody G3-245 or control IgG did not (Fig. 1B). These results indicate that Rb forms a complex in vivo not only with HDAC but also with c-Ski and mSin3A. We could not detect N-CoR or SMRT in the complex immunoprecipitated with anti-Rb antibodies (data not shown). However, we cannot exclude the possibility that this is due to the low level of expression of N-CoR and SMRT in HeLa and CV-1 cells.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   Rb binds to the HDAC-mSin3A-c-Ski complex via a direct interaction with c-Ski and HDAC. A, co-immunoprecipitation of c-Ski and Rb. Lysates of HeLa cells were immunoprecipitated with anti-c-Ski, anti-Sno antibodies, or control anti-Gal4 antibody. The immunocomplex was analyzed on 9% SDS gels followed by Western blotting using anti-Rb antibody. B, complex formation between Rb and mSin3A. Lysates of CV-1 cells were immunoprecipitated with anti-Rb antibodies (G3-245 or XZ91) or normal IgG. The immunocomplexes were analyzed on 7.5% gel followed by Western blotting using anti-mSin3A antibodies. C, v-Ski inhibits association between Rb and HDAC1. CV-1 cells were transfected with a mixture of the c-Ski or v-Ski expression plasmid together with the plasmids to express HDAC1 and Gal4-Rb. Lysates prepared from transfected cells were immunoprecipitated with anti-Gal4 or control IgG antibody. The immunocomplex was analyzed on 9% SDS gels followed by Western blotting using anti-HDAC1 antibody. In the two lanes on the left, HDAC1 was detected by Western blotting using lysates to confirm that almost the same amount of HDAC1 was expressed in the presence of c-Ski or v-Ski.

To examine whether expression of v-Ski results in loss of HDAC in the Rb-HDAC complex, we performed the co-immunoprecipitation experiment (Fig. 1C). CV-1 cells were transfected with a mixture of the c-Ski or v-Ski expression plasmid together with the plasmids to express HDAC1 and the Gal4-Rb fusion protein made up of the Gal4 DNA-binding domain and the pocket region of Rb. The cell lysates were prepared and immunoprecipitated with anti-Gal4 or control IgG antibody. The amount of HDAC1 coprecipitated with Gal4-Rb in the presence of v-Ski was apparently less than that with c-Ski. These results suggest that v-Ski inhibits association between Rb and HDAC1 in a dominant negative fashion.

During the analysis of the interaction between Rb and the components of the N-CoR complex, we found that c-Ski directly binds to Rb in vitro. In the GST pull-down assays using in vitro translated Rb and the GST-c-Ski resin containing full-length c-Ski, a significant amount of in vitro translated Rb was found to bind to the GST-c-Ski resin (Fig. 2A). The results of binding assays using the different mutants of Rb indicated that the B subdomain in the pocket region of Rb is responsible for the interaction with c-Ski. To identify the region in c-Ski that interacts with Rb, the GST pull-down assay was performed using the GST-Rb fusion protein resin and various forms of in vitro translated c-Ski protein (Fig. 2B). The results indicated that two regions in c-Ski efficiently interact with Rb; one is the region between amino acids 197 and 330, which includes a part of the N-CoR-binding domain (amino acids 99-274) and the other is the C-terminal coiled-coil region (amino acids 556-728). Thus, Rb directly binds to c-Ski and HDAC.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   Domain analysis of Rb and c-Ski. A, deletion analysis of Rb. The various forms of Rb used are indicated. The results of binding assays are summarized on the right. The relative binding activities are designated + and -, which indicate the binding of 4-10% and less than 1% of the input protein, respectively. In the lower panel, in vitro translated Rb (Input) and Rb bound to GST-c-Ski were analyzed by SDS-PAGE followed by autoradiography. In the input lanes, the amount of Rb was 10% of that used for the binding assay. B, deletion analysis of c-Ski. The binding of various forms of in vitro translated c-Ski to the GST-Rb resin was examined as described above. GST-Rb contains the A and B pocket domains of Rb. The relative binding activities are designated ++, +, and -, which indicate the binding of 7-17%, 5-7%, and less than 3% of the input protein, respectively.

To further investigate whether c-Ski is required for transcriptional repression by Rb, antibody injection experiments were done (Fig. 3). Injection into Rat-1 cells of a lacZ reporter plasmid containing the lacZ gene linked to the TK promoter and Gal4-binding sites gave rise to many lacZ-positive cells. Co-injection of this lacZ reporter with a plasmid encoding the Gal4-Rb fusion protein made up of the Gal4 DNA-binding domain and the pocket region of Rb resulted in a decrease in the number of lacZ-positive cells. This decrease was relieved significantly by co-injection of anti-c-Ski antibody and partially by anti-Sno antibodies. Co-injection of both antibodies also significantly relieved the decrease in the number of lacZ-positive cells, but not completely. The incomplete abrogation of Gal-Rb function by co-injection of both antibodies may be due to the presence of other Ski-related protein(s) such as the third member of the ski gene family which we identified recently.2 As a control experiment, we used a Gal4 fusion protein containing the repressor domain of delta EF1, which is thought not to utilize the N-CoR c-Ski complex. Co-injection of anti-c-Ski or anti-Sno antibodies did not alleviate the decrease in the number of lacZ-positive cells induced by Gal4-delta EF1 (28), indicating that the effect of anti-Ski/Sno antibodies was specific for Rb.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   Abrogation of Rb-induced transcriptional repression by anti-Ski/Sno antibodies. The Gal4 site-containing lacZ reporter was injected along with the Gal4-Rb or the Gal4 expression plasmid and the green fluorescent protein (GFP) vector as a marker into the nuclei of Rat-1 cells. The expression of lacZ was monitored by X-gal staining. The effect of anti-Ski and anti-Sno antibodies on the number of lacZ-positive cells was examined by co-injection. Typical photomicrographs of X-gal staining and green fluorescence for the indicated constructs and antibodies are shown above. Experiments were repeated three times, and the number of injected cells in each experiment ranged from 132-202. The number of lacZ+ cells were quantified based on the percentage of injected cells that stained blue, and the results are presented below as bar graphs along with the standard deviation. The shaded bar shows significant abrogation of Rb-induced transcriptional repression by co-injection of anti-Ski and anti-Sno antibodies.

To investigate whether v-Ski mutants that lack the C-terminal region of c-Ski could abrogate transcriptional repression by Rb in a dominant negative fashion as in the case of Mad, we examined the effect of overexpression of v-Ski on Gal4-Rb-induced transcriptional repression (Fig. 4, A and B). Gal4-Rb containing the pocket region of Rb strongly repressed transcription from the Gal4 site-containing reporter. This Gal4-Rb-induced repression was abrogated by v-Ski in a dose-dependent manner. Furthermore, wild type c-Ski partly abrogated Gal4-Rb-induced transcriptional repression. We observed that the microspeckle pattern of N-CoR was disrupted by coexpression of a high amount of c-Ski but not by a low amount of c-Ski.3 These two observations are consistent with the idea that overexpression of wild type c-Ski abrogates transcriptional repression by creating an imbalance between the components of the co-repressor complex rather than potentiating transcriptional repression. In control experiments, repression by the Gal4-delta EF1 fusion protein was not abolished by co-expression of either v-Ski or wild type c-Ski (28). Using the E2F1 site-containing luciferase reporter, we also examined the effect of v-Ski on E2F1-mediated transcriptional activation (Fig. 4C). v-Ski was also found to enhance E2F1-induced transcriptional activation in a dose-dependent manner. These results indicate that v-Ski inhibits Rb-dependent transcriptional repression.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   V-Ski inhibits transcriptional repression by Rb. A, the structures of wild type c-Ski and v-Ski are indicated. B, v-Ski inhibits Gal4-Rb-induced transcriptional repression. A mixture of the Gal4 site-containing luciferase reporter, the Gal4-Rb or Gal4 expression plasmid, and the plasmid encoding v-Ski or c-Ski was transfected into CV-1 cells, and luciferase activity was measured. The amount of effector plasmid was 1 (+), 2 (++), or 3 µg (+++). The data shown are an average of three experiments ± S.E. The shaded bar indicates the data obtained with v-Ski or c-Ski. C, v-Ski enhances E2F1-induced transcriptional activation. A mixture of the E2F1 site-containing luciferase reporter, the E2F1 or control expression plasmid, and the v-Ski expression plasmid was transfected into CV-1 cells, and the luciferase activity was measured. The amount of v-Ski expression plasmid was 1.5 (+), 2.0 (++), or 2.5 µg (+++).


    DISCUSSION

The oncogene v-ski can transform chicken embryo fibroblasts. Our results indicate that v-Ski abrogates transcriptional repression mediated not only by Mad but also by Rb. c-Ski has two regions that are conserved in related proteins, the N-terminal cysteine-rich region and the C-terminal coiled-coil region. N-CoR binds to the N-terminal cysteine-rich region, while the C-terminal coiled-coil region binds to mSin3 (28). The C-truncated c-Ski protein lacking the coiled-coil region cannot bind to mSin3 and disrupts the dot-like structure of N-CoR (28), suggesting that this form of c-Ski acts as in a dominant negative fashion. Because v-Ski also lacks the C-terminal coiled-coil region, v-Ski probably inhibits Mad- and Rb-mediated transcriptional repression in a dominant negative fashion. In our co-transfection assay, overexpression of normal c-Ski also partly abrogated the transcriptional repression mediated by Rb (Fig. 4). This is consistent with the fact that overexpression of wild type c-Ski also leads to transformation (24). Mutation of the human Rb gene occurs in a wide variety of tumors (25). In addition, one of the mad-related genes, mxi1, was recently demonstrated to act as a tumor suppressor using mutant mice (26). Therefore, abrogation of Rb and Mad activity by v-Ski may contribute, at least partly, to transformation by v-ski.

Rb was recently reported to directly bind to HDAC (18-20). Our results indicate that Rb also directly interacts with c-Ski. Furthermore, Rb forms a complex with mSin3, although it is not clear whether the Rb-HDAC-mSin3A-Ski complex contains N-CoR. The antibody injection experiments showed that c-Ski is required for Rb-mediated transcriptional repression (Fig. 3). At present, it remains unknown whether N-CoR and mSin3 are needed for the transcriptional repression mediated by Rb. Thus, c-Ski is required for the transcriptional repression mediated by at least Mad, thyroid receptor, and Rb. It is possible that other transcriptional repressors that utilize the N-CoR-mSin3-HDAC complex also require c-Ski. The complex containing mSin3 consists of multiple proteins such as SAP30 and the histone-binding proteins RbAp46 and RbAp48 (27). Interestingly, SAP30 is required for the transcriptional repression mediated by the estrogen receptor but not by thyroid receptor or the retinoic acid receptor (7). To understand the molecular mechanism of v-Ski-induced transformation, it will be important to determine whether c-Ski acts in specific transcriptional repression mediated by a limited number of repressors or in transcriptional repression in general.

    ACKNOWLEDGEMENTS

We thank Dr. T. Dryja for the human Rb cDNA, Drs. K. Ohtani and M. Ikeda for the E2F site-containing luciferase reporter and the E2F1 expression plasmid, and Dr. S. L. Schreiber for the HDAC1 cDNA.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel On leave from the Dept. of Oncology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-0071, Japan.

¶¶ To whom correspondence should be addressed: Laboratory of Molecular Genetics, Tsukuba Life Science Center, RIKEN, 3-1-1 Koyadai, Tsukuba, Ibaraki 305, Japan. Tel.: 81-298-36-9031; Fax: 81-298-36-9030; E-mail: sishii{at}rtc.riken.go.jp.

    ABBREVIATIONS

The abbreviations used are: c-ski, cellular ski gene; c-Ski, c-ski gene product; HDAC, histone deacetylase; N-CoR, nuclear hormone receptor co-repressor; Rb, retinoblastoma gene product; v-Ski, viral ski gene product; sno, ski-related novel gene; PBS, phosphate-buffered saline; GST, glutathione S-transferase.

2 M. M. Khan, T. Nomura, and S. Ishii, unpublished data.

3 T. Nomura and S. Ishii, unpublished data.

    REFERENCES
Top
Abstract
Introduction
References

  1. Li, Y., Turck, C. M., Teumer, J. K., and Stavnezer, E. (1986) J. Virol. 57, 1065-1072[Medline] [Order article via Infotrieve]
  2. Nomura, N., Sasamoto, S., Ishii, S., Date, T., Matsui, M., and Ishizaki, R. (1989) Nucleic Acids Res. 17, 5489-5500[Abstract]
  3. Nagase, T., Mizuguchi, G., Nomura, N., Ishizaki, T., Ueno, Y., and Ishii, S. (1990) Nucleic Acids Res. 18, 337-343[Abstract]
  4. Stavnezer, E., Brodeur, D., and Brennan, L. A. (1989) Mol. Cell. Biol. 9, 4038-4045[Medline] [Order article via Infotrieve]
  5. Zheng, G., Teumer, J., Colmenares, C., Richmond, C., and Stavnezer, E. (1997) Oncogene 15, 459-471[CrossRef][Medline] [Order article via Infotrieve]
  6. Nagase, T., Nomura, N., and Ishii, S. (1993) J. Biol. Chem. 268, 13710-13716[Abstract/Free Full Text]
  7. Laherty, C. D., Billin, A. N., Lavinsky, R. M., Yochum, G. S., Bush, A. C., Sun, J.-M., Mullen, T.-M., Davie, J. R., Rose, D. W., Glass, C. K., Rosenfeld, M. G., Ayer, D. E., and Eisenman, R. N. (1998) Mol. Cell 2, 33-42[Medline] [Order article via Infotrieve]
  8. Hörlein, A. J., Näär, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Söderström, M., Glass, C. K., and Rosenfeld, M. G. (1995) Nature 377, 397-404[CrossRef][Medline] [Order article via Infotrieve]
  9. Chen, J. D., and Evans, R. M. (1995) Nature 377, 454-457[CrossRef][Medline] [Order article via Infotrieve]
  10. Heinzel, T., Lavinsky, R. M., Mullen, T.-M., Söderström, M., Laherty, C. D., Torchia, J., Yang, W.-M., Brard, G., Ngo, S. D., Davie, J. R., Seto, E., Eisenman, R. N., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1997) Nature 387, 43-48[CrossRef][Medline] [Order article via Infotrieve]
  11. Alland, L., Muhle, R., Hou, H., Jr., Potes, J., Chin, L., Schreiber-Agus, N., and DePinho, R. A. (1997) Nature 387, 49-55[CrossRef][Medline] [Order article via Infotrieve]
  12. Hassing, C. A., Fleischer, T. C., Billin, A. N., Schreiber, S. L., and Ayer, D. E. (1997) Cell 89, 341-347[Medline] [Order article via Infotrieve]
  13. Laherty, C. D., Yang, W.-M., Sun, J.-M., Davie, J. R., Seto, E., and Eisenman, R. N. (1997) Cell 89, 349-356[Medline] [Order article via Infotrieve]
  14. Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., and Evans, R. M. (1997) Cell 89, 373-380[Medline] [Order article via Infotrieve]
  15. Ayer, D. E., Kretzner, L., and Eisenman, R. N. (1993) Cell 72, 211-222[Medline] [Order article via Infotrieve]
  16. Ayer, D. E., and Eisenman, R. N. (1993) Genes Dev. 7, 2110-2119[Abstract]
  17. Roussel, M. F., Ashmun, R. A., Sher, C. J., Eisenman, R. N., and Ayer, D. E. (1996) Mol. Cell. Biol. 16, 2796-2801[Abstract]
  18. Brehm, A., Miska, E. A., McCance, D. J., Reid, J. L., Bannister, A. J., and Kouzarides, T. (1998) Nature 391, 597-601[CrossRef][Medline] [Order article via Infotrieve]
  19. Magnaghi-Jaulin, L., Groisman, R., Naguibneva, I., Robin, P., Lorain, S., Le Villain, J. P., Troalen, F., Trouche, D., and Harel-Bellan, A. (1998) Nature 391, 601-605[CrossRef][Medline] [Order article via Infotrieve]
  20. Luo, R. X., Postigo, A. A., and Dean, D. C. (1998) Cell 92, 463-473[Medline] [Order article via Infotrieve]
  21. Weinberg, R. A. (1995) Cell 81, 323-330[Medline] [Order article via Infotrieve]
  22. Nevins, J. R. (1992) Science 258, 424-429[Medline] [Order article via Infotrieve]
  23. Ohtani, K., and Nevins, J. R. (1994) Mol. Cell. Biol. 14, 1603-1612[Abstract]
  24. Colmenares, C., Sutrave, P., Hughes, S. H., and Stavnezer, E. (1991) J. Virol. 65, 4929-4935[Medline] [Order article via Infotrieve]
  25. Goodrich, D. W., and Lee, W. H. (1993) Biochim. Biophys. Acta 1155, 43-61[CrossRef][Medline] [Order article via Infotrieve]
  26. Schreiber-Agus, N., Meng, Y., Hoang, T., Hou, H., Jr., Chen, K., Greenberg, R., Cordon-Cardo, C., Lee, H.-W., and DePinho, R. A. (1998) Nature 393, 483-487[CrossRef][Medline] [Order article via Infotrieve]
  27. Zhang, Y., Iratni, R., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. (1997) Cell 89, 357-364[Medline] [Order article via Infotrieve]
  28. Nomura, T., Khan, M. M., Kaul, S. C., Dong, H.-D., Wadhwa, R., Colmenares, C., and Ishii, S. (1999) Genes Dev., in press


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.